Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UX-DA003 in Parkinson's Disease
NCT07911670Phase 1Recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Nov 2026
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of UX-DA003 in Parkinson's disease (PD), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoint: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) at 6 months. Started Nov 2026; status: recruiting.
02
Drugs
UX-DA003
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07911670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07911670.